New Haven, CTNCT06142955Now EnrollingIRB Ready

Autism Spectrum Disorder Clinical Trial in New Haven, CT

Access cutting-edge autism spectrum disorder treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.

Sponsored by Yale University

Quick Self-Assessment

See if you qualify for this New Haven location

Preparing your pre-screening questions…

Expert Care in New Haven

Access autism spectrum disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related autism spectrum disorder treatment provided free

Apply for This New Haven Location

Check if you qualify for this autism spectrum disorder clinical trial in New Haven, CT

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to New Haven

    Convenient for CT residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit New Haven site if eligible
  4. 4Begin participation

About This Autism Spectrum Disorder Study in New Haven

This study will assess clinical and behavioral measures along with electroencephalogram (EEG), event-related potentials (ERPS), and eye-tracking (ET) prior to and following a single intermittent Theta Burst Stimulation (iTBS) session to provide preliminary insight into the potential of TMS as an intervention for depression in individuals with Autism Spectrum Disorder (ASD).

Sponsor: Yale University

Who Can Participate

Inclusion Criteria

Individuals from Yale University and the surrounding community who are between the ages of 18 and 40 years old with or without a diagnosis of depression. Or individuals between the ages of 18 and 40 years old with a diagnosis of autism spectrum disorder, autistic disorder, PDD NOS, or Asperger syndrome with or without a diagnosis of depression.
A depression score on the HDRS-17 of at least 20 will be used as a cut-off for depression.
Participants are unmedicated or on stable medication treatment for at least two weeks.
Willingness and ability to participate in an EEG and eye-tracking procedure.
Provision of signed and dated informed consent.

Exclusion Criteria

Participants reporting significant head trauma or serious brain illness.
Participants unable to provide signed informed consent.
Participants with major psychiatric illness that would preclude completion of study measures. Participants with diagnosis of a psychotic or bipolar illness with be excluded.
Participants with a history of serious medical illness, stroke, seizures, epileptiform EEG abnormalities, or family history of epilepsy.
Participants taking prescription medications that may affect cognitive processes under study.
Participants taking any medication that may increase their risk of seizures.
Participants who have taken alcohol or recreational drugs within the preceding 24 hours prior to the scheduled study visit as determined by the urine toxicology test.
Participants with a history of substance or alcohol abuse or dependence in the past 6 months.
Participants with a significant risk of suicide or a h/o suicide attempt in the last 6 months. Participants with active suicidal ideation will be excluded from the study.
Females of known/suspected pregnancy or who test positive on a pregnancy test.
Participants with a history of metalworking or injury by shrapnel or metallic objects.
Participants with a history of prior TMS therapy or use of an investigational drug within 12 weeks of visit
Participants with an IQ below 80 (as confirmed by the WASI, Wechsler Abbreviated Scale of Intelligence)

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New Haven?

Yes, this clinical trial (NCT06142955) has an active research site in New Haven, CT that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Autism Spectrum Disorder Treatment Options in New Haven, CT

If you're searching for autism spectrum disorder treatment options in New Haven, CT, this clinical trial (NCT06142955) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced autism spectrum disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all autism spectrum disorder clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in New Haven, CT

See all pulmonary embolism clinical trials recruiting in New Haven — not just this study.

Browse Pulmonary Embolism Trials in New Haven →

Browse More Trials by Condition

Pulmonary Embolism TrialsAutism TrialsUTI TrialsAll Conditions →

Ready to Join in New Haven?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · New Haven, CT